| Year |
Citation |
Score |
| 2024 |
Myers CG, Viswambharan H, Haywood NJ, Bridge K, Turvey S, Armstrong T, Lunn L, Meakin PJ, Porter KE, Clavane EM, Beech DJ, Cubbon RM, Wheatcroft SB, McPhillie MJ, Issad T, ... ... Simmons KJ, et al. Small molecule modulation of insulin receptor-insulin like growth factor-1 receptor heterodimers in human endothelial cells. Molecular and Cellular Endocrinology. 594: 112387. PMID 39419341 DOI: 10.1016/j.mce.2024.112387 |
0.479 |
|
| 2020 |
Scott C, Kankanala J, Foster TL, Goldhill DH, Bao P, Simmons K, Pingen M, Bentham M, Atkins E, Loundras E, Elderfield R, Claridge JK, Thompson J, Stilwell PR, Tathineni R, et al. Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza. Plos Pathogens. 16: e1008716. PMID 32780760 DOI: 10.1371/Journal.Ppat.1008716 |
0.344 |
|
| 2020 |
King RJ, Schuett K, Tiede C, Jankowski V, John V, Trehan A, Simmons K, Ponnambalam S, Storey RF, Fishwick CWG, McPherson MJ, Tomlinson DC, Ajjan RA. Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk. Haematologica. PMID 32354869 DOI: 10.3324/Haematol.2019.239558 |
0.339 |
|
| 2017 |
Ozsvari B, Sotgia F, Simmons K, Trowbridge R, Foster R, Lisanti MP. Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs). Oncotarget. 8: 78340-78350. PMID 29108233 DOI: 10.18632/Oncotarget.21259 |
0.35 |
|
| 2016 |
King R, Schuett K, Tiede C, Jankowski V, John V, Trehan A, Simmons K, Ponnambalam S, Fishwick C, McPherson M, Tomlinson D, Ajjan R. P43 Complement C3 in diabetes: hypofibrinolysis, glycation and inhibiting interaction with fibrinogen to reduce cardiovascular risk Heart. 102. DOI: 10.1136/Heartjnl-2016-310696.47 |
0.333 |
|
| 2015 |
King R, Tiede C, Simmons K, Fishwick C, Tomlinson D, Ajjan R. Inhibition of complement C3 and fibrinogen interaction: a potential novel therapeutic target to reduce cardiovascular disease in diabetes. Lancet (London, England). 385: S57. PMID 26312879 DOI: 10.1016/S0140-6736(15)60372-5 |
0.547 |
|
| 2015 |
Caseley EA, Muench SP, Baldwin SA, Simmons K, Fishwick CW, Jiang LH. Docking of competitive inhibitors to the P2X7 receptor family reveals key differences responsible for changes in response between rat and human. Bioorganic & Medicinal Chemistry Letters. PMID 26099538 DOI: 10.1016/J.Bmcl.2015.06.001 |
0.596 |
|
| 2015 |
McPhillie MJ, Cain RM, Narramore S, Fishwick CW, Simmons KJ. Computational methods to identify new antibacterial targets. Chemical Biology & Drug Design. 85: 22-9. PMID 24974974 DOI: 10.1111/Cbdd.12385 |
0.568 |
|
| 2014 |
Cain R, Narramore S, McPhillie M, Simmons K, Fishwick CW. Applications of structure-based design to antibacterial drug discovery. Bioorganic Chemistry. 55: 69-76. PMID 24962384 DOI: 10.1016/J.Bioorg.2014.05.008 |
0.584 |
|
| 2014 |
Simmons KJ, Jackson SM, Brueckner F, Patching SG, Beckstein O, Ivanova E, Geng T, Weyand S, Drew D, Lanigan J, Sharples DJ, Sansom MS, Iwata S, Fishwick CW, Johnson AP, et al. Molecular mechanism of ligand recognition by membrane transport protein, Mhp1. The Embo Journal. 33: 1831-44. PMID 24952894 DOI: 10.15252/Embj.201387557 |
0.629 |
|
| 2014 |
Lolicato M, Bucchi A, Arrigoni C, Zucca S, Nardini M, Schroeder I, Simmons K, Aquila M, DiFrancesco D, Bolognesi M, Schwede F, Kashin D, Fishwick CW, Johnson AP, Thiel G, et al. Cyclic dinucleotides bind the C-linker of HCN4 to control channel cAMP responsiveness. Nature Chemical Biology. 10: 457-62. PMID 24776929 DOI: 10.1038/Nchembio.1521 |
0.586 |
|
| 2014 |
Moroni A, Lolicato M, Bucchi A, Arrigoni C, Zucca S, Nardini M, Simmons K, Aquila M, Schwede F, Thiel G, Bolognesi M, DiFrancesco D. Discovery and Characterization of a Distinct Cyclic Nucleotide Binding Pocket in HCN Channels Biophysical Journal. 106: 627a. DOI: 10.1016/J.Bpj.2013.11.3470 |
0.39 |
|
| 2013 |
Simmons KJ, Gotfryd K, Billesbølle CB, Loland CJ, Gether U, Fishwick CW, Johnson AP. A virtual high-throughput screening approach to the discovery of novel inhibitors of the bacterial leucine transporter, LeuT. Molecular Membrane Biology. 30: 184-94. PMID 22908980 DOI: 10.3109/09687688.2012.710341 |
0.577 |
|
| 2012 |
Wacker SJ, Jurkowski W, Simmons KJ, Fishwick CW, Johnson AP, Madge D, Lindahl E, Rolland JF, de Groot BL. Identification of selective inhibitors of the potassium channel Kv1.1-1.2((3)) by high-throughput virtual screening and automated patch clamp. Chemmedchem. 7: 1775-83. PMID 22473914 DOI: 10.1002/Cmdc.201100600 |
0.542 |
|
| 2011 |
Woon EC, Zervosen A, Sauvage E, Simmons KJ, Zivec M, Inglis SR, Fishwick CW, Gobec S, Charlier P, Luxen A, Schofield CJ. Structure guided development of potent reversibly binding penicillin binding protein inhibitors. Acs Medicinal Chemistry Letters. 2: 219-23. PMID 24900305 DOI: 10.1021/Ml100260X |
0.586 |
|
| 2010 |
Miller K, Dunsmore CJ, Leeds JA, Patching SG, Sachdeva M, Blake KL, Stubbings WJ, Simmons KJ, Henderson PJ, De Los Angeles J, Fishwick CW, Chopra I. Benzothioxalone derivatives as novel inhibitors of UDP-N-acetylglucosamine enolpyruvyl transferases (MurA and MurZ). The Journal of Antimicrobial Chemotherapy. 65: 2566-73. PMID 20861142 DOI: 10.1093/Jac/Dkq349 |
0.627 |
|
| 2010 |
Simmons KJ, Chopra I, Fishwick CW. Structure-based discovery of antibacterial drugs. Nature Reviews. Microbiology. 8: 501-10. PMID 20551974 DOI: 10.1038/Nrmicro2349 |
0.566 |
|
| 2009 |
Blake KL, O'Neill AJ, Mengin-Lecreulx D, Henderson PJ, Bostock JM, Dunsmore CJ, Simmons KJ, Fishwick CW, Leeds JA, Chopra I. The nature of Staphylococcus aureus MurA and MurZ and approaches for detection of peptidoglycan biosynthesis inhibitors. Molecular Microbiology. 72: 335-43. PMID 19298367 DOI: 10.1111/J.1365-2958.2009.06648.X |
0.559 |
|
| Show low-probability matches. |